{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:46:38Z","timestamp":1788281198665,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clgc.2024.02.011","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T17:52:14Z","timestamp":1708710734000},"page":"102060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)"],"prefix":"10.1016","volume":"22","author":[{"given":"Jeffrey","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney H.","family":"Breau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-304X","authenticated-orcid":false,"given":"Simon","family":"Tanguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9907-9112","authenticated-orcid":false,"given":"Aly-Khan","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-9837","authenticated-orcid":false,"given":"Bimal","family":"Bhindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4032-6120","authenticated-orcid":false,"given":"Antonio","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Fallah-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-4026","authenticated-orcid":false,"given":"Vincent","family":"Castonguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3163-9902","authenticated-orcid":false,"given":"Naveen S.","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1533-3815","authenticated-orcid":false,"given":"Denis","family":"Souli\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Pouliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6903-5357","authenticated-orcid":false,"given":"Georg A.","family":"Bjarnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clgc.2024.02.011_bib0001","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5489\/cuaj.7245","article-title":"Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021","volume":"15","author":"Christina Canil","year":"2021","journal-title":"Can Urol Assoc J"},{"issue":"3","key":"10.1016\/j.clgc.2024.02.011_bib0002","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/OP.21.00419","article-title":"Clinical Review on the Management of Metastatic Renal Cell Carcinoma","volume":"18","author":"Tran","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.clgc.2024.02.011_bib0003","first-page":"172","article-title":"Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors","volume":"11","author":"Schmidinger","year":"2013","journal-title":"EJC Suppl EJC Off J EORTC Eur Organ Res Treat Cancer Al"},{"issue":"9","key":"10.1016\/j.clgc.2024.02.011_bib0004","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.clgc.2024.02.011_bib0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.clgc.2019.01.015","article-title":"COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma","volume":"17","author":"Sternberg","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2024.02.011_bib0006","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2023.41.16_suppl.4528","article-title":"Effect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for advanced renal cell carcinoma","volume":"41","author":"Nuvola","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.02.011_bib0007","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3233\/KCA-190077","article-title":"Individualization of Dose and Schedule Based On Toxicity for Oral VEGF Drugs in Kidney Cancer","volume":"3","author":"Parmar","year":"2019","journal-title":"Kidney Cancer"},{"issue":"5_suppl","key":"10.1016\/j.clgc.2024.02.011_bib0008","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1200\/jco.2012.30.5_suppl.363","article-title":"A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status","volume":"30","author":"Khosravan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.02.011_bib0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12032-017-0928-z","article-title":"Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients","volume":"34","author":"Buda-Nowak","year":"2017","journal-title":"Med Oncol Northwood Lond Engl"},{"issue":"12","key":"10.1016\/j.clgc.2024.02.011_bib0010","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/annonc\/mds145","article-title":"Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study","volume":"23","author":"Poprach","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.02.011_bib0011","first-page":"69","article-title":"The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial","volume":"108","author":"Bjarnason","year":"2019","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"10","key":"10.1016\/j.clgc.2024.02.011_bib0012","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(19)30513-3","article-title":"Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study","volume":"20","author":"Ornstein","year":"2019","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.clgc.2024.02.011_bib0013","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clgc.2024.02.011_bib0014","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2024.02.011_bib0015","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cam4.3717","article-title":"Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"10","author":"Gan","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.clgc.2024.02.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102062","article-title":"Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care","volume":"89","author":"Castellano","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.clgc.2024.02.011_bib0017","first-page":"E499","article-title":"Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population","volume":"14","author":"Tajzler","year":"2020","journal-title":"Can Urol Assoc J J Assoc Urol Can"},{"issue":"6","key":"10.1016\/j.clgc.2024.02.011_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100312","article-title":"Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics\/pharmacodynamics study","volume":"6","author":"Cerbone","year":"2021","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.clgc.2024.02.011_bib0019","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00280-018-3579-7","article-title":"Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma","volume":"81","author":"Lacy","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.clgc.2024.02.011_bib0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3233\/KCA-210117","article-title":"Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma","volume":"6","author":"Sharma","year":"2022","journal-title":"Kidney Cancer Clifton Va"},{"key":"10.1016\/j.clgc.2024.02.011_bib0021","first-page":"102","article-title":"Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program","volume":"142","author":"Albiges","year":"2021","journal-title":"Eur J Cancer Oxf Engl 1990"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T07:59:50Z","timestamp":1717660790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1558767324000338"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.02.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102060"}}